{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rosacea&page=4",
    "query": {
      "condition": "Rosacea",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 148,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rosacea&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rosacea&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T22:06:36.995Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01735201",
      "title": "AGN-199201 for the Treatment of Erythema With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea",
        "Erythema"
      ],
      "interventions": [
        {
          "name": "AGN-199201 Dose A",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Dose B",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Dose C",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 357,
      "start_date": "2012-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735201"
    },
    {
      "nct_id": "NCT00945373",
      "title": "Combination Therapy for the Treatment of Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erythematotelangiectatic Rosacea"
      ],
      "interventions": [
        {
          "name": "calcium dobesilate",
          "type": "DRUG"
        },
        {
          "name": "pulsed dye laser",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ellen Marmur",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2009-07",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2019-06-17",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00945373"
    },
    {
      "nct_id": "NCT01579084",
      "title": "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rosacea",
        "Erythema"
      ],
      "interventions": [
        {
          "name": "AGN-199201 Formulation A",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Formulation B",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Formulation C",
          "type": "DRUG"
        },
        {
          "name": "AGN-199201 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2012-04",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579084"
    },
    {
      "nct_id": "NCT05597462",
      "title": "Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Minocycline hydrochloride capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Journey Medical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2022-09-30",
      "completion_date": "2023-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 2,
      "location_summary": "Las Cruces, New Mexico • El Paso, Texas",
      "locations": [
        {
          "city": "Las Cruces",
          "state": "New Mexico"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05597462"
    },
    {
      "nct_id": "NCT02144181",
      "title": "Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Erythematotelangiectatic Rosacea",
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Ulthera System Treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Ulthera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 88,
      "start_date": "2014-05",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 4,
      "location_summary": "Omaha, Nebraska • Wilmington, North Carolina • Hummelstown, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Wilmington",
          "state": "North Carolina"
        },
        {
          "city": "Hummelstown",
          "state": "Pennsylvania"
        },
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02144181"
    },
    {
      "nct_id": "NCT01045551",
      "title": "Open Label Pilot Study of Apremilast in Treatment of Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Erythematotelangiectatic Rosacea",
        "Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Julian M. Mackay-Wiggan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-06",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-12-13",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01045551"
    },
    {
      "nct_id": "NCT06072066",
      "title": "Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rosacea",
        "Systemic Inflammation"
      ],
      "interventions": [
        {
          "name": "Skin Barrier Oral Supplement",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Integrative Skin Science and Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-11-22",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072066"
    },
    {
      "nct_id": "NCT04153188",
      "title": "Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Erythematotelangiectatic Rosacea"
      ],
      "interventions": [
        {
          "name": "The Vbeam® Prima System",
          "type": "DEVICE"
        },
        {
          "name": "Oxymetazoline HCL 1% Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Candela Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-01-15",
      "completion_date": "2021-01-05",
      "has_results": true,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04153188"
    },
    {
      "nct_id": "NCT05592548",
      "title": "Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rosacea, Papulopustular"
      ],
      "interventions": [
        {
          "name": "cold atmospheric plasma",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The Skin Center Dermatology Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2024-01-02",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "New City, New York",
      "locations": [
        {
          "city": "New City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05592548"
    },
    {
      "nct_id": "NCT00892281",
      "title": "ORCA - Oracea® for Rosacea: A Community-based Assessment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "doxycycline (Oracea®) 40 mg modified release as monotherapy",
          "type": "DRUG"
        },
        {
          "name": "doxycycline (Oracea®) 40 mg modified release as add-on therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1421,
      "start_date": "2009-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-10-21T22:06:36.995Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00892281"
    }
  ]
}